356 related articles for article (PubMed ID: 23688841)
1. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic impurities in pharmaceuticals: a critique of the derivation of the cancer TTC (Threshold of Toxicological Concern) and recommendations for structural-class-based limits.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2013 Nov; 67(2):299-316. PubMed ID: 23988886
[TBL] [Abstract][Full Text] [Related]
3. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
Ellis P; Kenyon M; Dobo K
Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
[TBL] [Abstract][Full Text] [Related]
4. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
5. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
6. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
7. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
8. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
11. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
[TBL] [Abstract][Full Text] [Related]
12. Origin of the TTC values for compounds that are genotoxic and/or carcinogenic and an approach for their re-evaluation.
Boobis A; Brown P; Cronin MTD; Edwards J; Galli CL; Goodman J; Jacobs A; Kirkland D; Luijten M; Marsaux C; Martin M; Yang C; Hollnagel HM
Crit Rev Toxicol; 2017 Sep; 47(8):705-727. PubMed ID: 28510487
[TBL] [Abstract][Full Text] [Related]
13. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies.
Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF
Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097
[TBL] [Abstract][Full Text] [Related]
14. Quantitative correlation of mutagenic and carcinogenic potencies for heterocyclic amines from cooked foods and additional aromatic amines.
Hatch FT; Knize MG; Moore DH; Felton JS
Mutat Res; 1992 Jun; 271(3):269-87. PubMed ID: 1378200
[TBL] [Abstract][Full Text] [Related]
15. The Threshold of Toxicological Concern (TTC) in risk assessment.
Munro IC; Renwick AG; Danielewska-Nikiel B
Toxicol Lett; 2008 Aug; 180(2):151-6. PubMed ID: 18573621
[TBL] [Abstract][Full Text] [Related]
16. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
17. Comparison of carcinogenic and in vivo genotoxic potency estimates.
Sanner T; Dybing E
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):131-9. PubMed ID: 15679476
[TBL] [Abstract][Full Text] [Related]
18. An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals.
Delaney EJ
Regul Toxicol Pharmacol; 2007 Nov; 49(2):107-24. PubMed ID: 17888551
[TBL] [Abstract][Full Text] [Related]
19. Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.
Bercu JP; Galloway SM; Parris P; Teasdale A; Masuda-Herrera M; Dobo K; Heard P; Kenyon M; Nicolette J; Vock E; Ku W; Harvey J; White A; Glowienke S; Martin EA; Custer L; Jolly RA; Thybaud V
Regul Toxicol Pharmacol; 2018 Apr; 94():172-182. PubMed ID: 29408293
[TBL] [Abstract][Full Text] [Related]
20. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
